Royalty Pharma expects 2022 Adj. Cash Receipts ~$2.79B, at upper end of guidance; 31% YoY growth

Royalty Pharma plc

2022-FY EPS reported $0.10 revenue$2,237,215,000

2022 Adjusted Cash Receipts (non-GAAP) expected ~$2,785-2,790M, towards upper end of $2,750-2,800M guidance; 31% YoY growth.
2022 GAAP operating cash flow expected ~$2,140-2,150M.
Since 2020, announced $10B in transactions; investments expected to add ~$1B to annual Adjusted Cash Receipts in 2025.
Added royalties on six new therapies in 2022, including Trelegy (respiratory), olpasiran, aficamten, and MK-8189.
Capital deployment target $10-12B over five years; potential to double to $4-5B annually longer term.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.